A Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in Chinese People

SARS-CoV-2 Clinical Trial

Official title:

A Cohort Study to Evaluate Safety and Immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in Participants Aged 18 Years and Over in China

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05549206
• Other study ID #: LVRNA012-IIT-03
• Status: Not yet recruiting
• Phase: N/A
• Start date: April 2023
• Est. completion date: April 2024

Study information

• Verified date: September 2022
• Source: AIM Vaccine Co., Ltd.
• Contact: Huan Zhou
• Phone: 05523086943
• Email: byyfygcp[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a cohort study to evaluate safety and immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in participants aged 18 years and over in China

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 350
• Est. completion date: April 2024
• Est. primary completion date: April 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age at the time of first dose of vaccine: adults aged 18-59 years (including boundary values), elderly =60 years, both sexes;

• Armpit temperature <37.3? on the day of enrollment;

• Based on the medical history and relevant physical examination and laboratory examination results, the investigator clinically determined that the patient was in good health;

• Subjects have independent judgment ability, can read, understand and complete vaccination diary cards, and they participate voluntarily and sign an informed consent form.

Exclusion Criteria:

• The subject has a history of SARS-CoV-2 or SARS infection, or has a history of contact with SARS-CoV-2 infected persons (nucleic acid test positive) or suspected infected persons within 30 days before screening, or living abroad within 30 days before screening history, or a positive SARS-CoV-2 nucleic acid test or a positive SARS-CoV-2 IgM or IgG test before the first dose of vaccine;

• History of allergy to any component of the study vaccine or a history of a severe allergic reaction to the vaccine or drug (including but not limited to anaphylactic shock, anaphylactic laryngeal edema, anaphylactic purpura, thrombocytopenic purpura, or local anaphylactic necrosis [Arthus reaction]);

• Upon questioning, have a history of COVID-19 vaccination, or have received other inactivated vaccines within 14 days before screening, and received live attenuated vaccines within 28 days;

• Patients have a medical history or family history of epilepsy, convulsions, neurological diseases and mental diseases;

• There are contraindications for intramuscular injection, such as: thrombocytopenia that has been diagnosed, any coagulation disorder or receiving anticoagulant treatment, etc.;

• The investigator judges that he is known or suspected of having more serious diseases at the same time, including but not limited to: respiratory diseases (tuberculosis, lung failure, etc.), liver and kidney diseases, cardiovascular diseases (heart failure, severe hypertension, etc.), Malignant tumor, infection or allergic skin disease, HIV infection (test report can be provided), or during the active period of acute infection or chronic disease (within 3 days before vaccination);

• Congenital malformations, developmental disorders, or chronic diseases that the investigator judges are not suitable for participating in this study (such as Downs syndrome, sickle cell anemia or neurological disorders, Guillain-Barre syndrome, etc.), excluding stable diabetes/hypertension );

• Patients with known immunological impairment or low immunological function diagnosed by the hospital before enrollment, or functional asplenia or splenectomy caused by any situation;

• During the screening period, laboratory tests (ALT, AST, troponin, D-dimer) and electrocardiogram abnormalities were clinically significant;

• Those with evidence of tobacco, alcohol, and drug abuse, and those who did not agree to abstain from smoking and drinking during the study period;

• Female: those who have a positive blood pregnancy test, are pregnant, breastfeeding, or have a pregnancy plan within one year; men: whose spouse has a pregnancy plan within one year;

• Patients have participated in other clinical trials (drugs, biological products or devices) within 3 months before the first dose of vaccine, or plan to participate in other clinical trials during the research period;

• Patients received immune enhancement or immunosuppressive therapy within 6 months before the first dose of vaccine (continuous oral or instillation for more than 14 days);

• Patients donated blood =400 ml within 28 days before screening, or received whole blood, plasma and immunoglobulin therapy within 6 months before screening;

• Currently receiving research drug treatment to prevent COVID-19;

• Patients are taking antipyretic, analgesic and anti-allergic drugs within 3 days before enrollment;

• The investigator judges that the subjects cannot follow the research procedures, comply with the agreement, or plan to permanently relocate from the area before the end of the research, or plan to leave the local area for a long time during the scheduled visit period;

• The relevant staff involved in this study or their immediate family members (such as spouses, parents, siblings or children);

• According to the investigator's judgment, there are other situations that are not suitable for participating in this clinical trial.

Related Conditions & MeSH terms

• SARS-CoV-2

Intervention

Biological:
• SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose
50µg/dose
• SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine high dose
100µg/dose

Drug:
• Placebo
Saline solution

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
AIM Vaccine Co., Ltd.	First Affiliated Hospital Bengbu Medical College, Ningbo Rongan Biological Pharmaceutical Co. Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	SARS-CoV-2 Novel coronavirus S protein antibody (IgG) level		At 28 days after full immunization
Primary	The levels of neutralizing antibodies of SARS-CoV-2 anti-Novel coronavirus 2019 (Omicron BA.2, BA.4, BA.5 and Delta strains) true virus		At 28 days after full immunization
Primary	The levels of neutralizing antibodies of SARS-CoV-2 anti-Novel coronavirus 2019 (Omicron BA.2, BA.4, BA.5 and Delta strains) pseudovirus		At 28 days after full immunization
Secondary	Incidence of adverse events		Within 14 days and 28 days after each dose of immunization
Secondary	Incidence of adverse events associated with the study vaccine		Within 14 days and 28 days after each dose of immunization
Secondary	Incidence of SAE		Within 28 days, 3 months, 6 months, and 12 months after the first dose of immunization to full immunization
Secondary	Incidence of AESI		Within 28 days, 3 months, 6 months, and 12 months after the first dose of immunization to full immunization
Secondary	Incidence of SAE associated with the study vaccine		Within 28 days, 3 months, 6 months, and 12 months after the first dose of immunization to full immunization
Secondary	Incidence of AESI associated with the study vaccine		Within 28 days, 3 months, 6 months, and 12 months after the first dose of immunization to full immunization
Secondary	Incidence of grade =3 adverse events	Adverse events were graded from pain, tenderness, itching, induration, swelling and other aspects, and the higher the grade, the more serious the adverse events were	Within 28 days after each dose/full dose
Secondary	Incidence of grade =3 adverse events associated with the study vaccine	Adverse events were graded from pain, tenderness, itching, induration, swelling and other aspects, and the higher the grade, the more serious the adverse events were	Within 28 days after each dose/full dose
Secondary	Statistics of withdrawal from the study due to adverse events		Within 28 days after each dose/full dose
Secondary	The level of SARS-CoV-2 S protein antibody (IgG)		At 14 days, 3 months, 6 months, and 12 months after full immunization
Secondary	The positive conversion rate of SARS-CoV-2 S protein antibody		At 14 days, 28 days, 3 months, 6 months, and 12 months after full immunization
Secondary	True virus neutralizing antibody levels of SARS-CoV-2 (Omicron strain BA.2, BA.4, BA.5, Delta strain)		At 14 days, 3 months, 6 months, and 12 months after full immunization
Secondary	Pseudovirus neutralizing antibody levels of SARS-CoV-2 (Omicron strain BA.2, BA.4, BA.5, Delta strain)		At 14 days, 3 months, 6 months, and 12 months after full immunization
Secondary	Positive conversion rates of neutralizing antibodies against true virus of SARS-CoV-2 (Omicron strain BA.2, BA.4, BA.5, Delta strain)		At 14 days, 28 days, 3 months, 6 months, and 12 months after full immunization
Secondary	Positive conversion rates of neutralizing antibodies against pseudovirus of SARS-CoV-2 (Omicron strain BA.2, BA.4, BA.5, Delta strain)		At 14 days, 28 days, 3 months, 6 months, and 12 months after full immunization
Secondary	Cellular immune response levels (IFN-?) against Novel coronavirus (2019-nCoV)(ELISPOT)		At 7 days , 14 days , and 28 days after complete immunization
Secondary	Cellular immune response levels ( IL-2) against Novel coronavirus (2019-nCoV)(ELISPOT)		At 7 days , 14 days , and 28 days after complete immunization
Secondary	Cellular immune response levels (IL-4) against Novel coronavirus (2019-nCoV)(ELISPOT)		At 7 days , 14 days , and 28 days after complete immunization
Secondary	Cellular immune response levels (IL-13) against Novel coronavirus (2019-nCoV)(ELISPOT)		At 7 days , 14 days , and 28 days after complete immunization